Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads.
Variables effecting removal of neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads were studied. Human neuroblastoma cell lines were labeled with the supravital DNA stain Hoechst 33342, seeded into normal bone marrow, incubated with monoclonal antibodies recognizing neuroblastoma cell surface antigens (HSAN 1.2, antibody 459, antibody 390, BA-1, and Leu-7), and then mixed with magnetic microspheres coated with goat anti-mouse immunoglobulin. Tumor cells that attached to the magnetic immunobeads were then removed from the marrow with magnets. The efficacy of tumor cell removal depended on the amount of monoclonal antibody bound to tumor cells and the immunobead/tumor cell ratio. In addition, two cycles of purging with both monoclonal antibodies and immunobeads was superior to one cycle. Using a cocktail of the five antibodies, 3 to 4 logs of tumor cells could be depleted from marrow with good recovery of viable hematopoietic cells.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001562:Benzimidazoles; D001853:Bone Marrow / Q000473:pathology*; D003429:Cross Reactions; D004306:Dose-Response Relationship, Immunologic; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D008280:Magnetics; D008954:Models, Biological; D009447:Neuroblastoma / Q000276:immunology / Q000473:pathology* / Q000628:therapy
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001562:Benzimidazoles; C017807:bisbenzimide ethoxide trihydrochloride